Human Longevity Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Human Longevity Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11333
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Human Longevity Inc (HLI) is a genomics-based technology company that develops sequenced genomes and phenotypic database. The company’s discovery capabilities include streamlining drug development, rescuing and repurposing drugs from failed clinical trials and discovery of biomarker and companion diagnostics. It focuses on therapeutic areas such as cancer, diabetes and obesity, heart and liver diseases, neurodegenerative and neurovascular disease, metabolic disease, and dementia. The company supports predictive, preventive and personalized care including the cancer analysis, integrated health analysis, newborn screening and rare, undiagnosed diseases through its genome sequencing and analysis. HLI is headquartered in San Diego, California, the US.

Human Longevity Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Human Longevity Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Human Longevity Inc, Medical Devices Deals, 2012 to YTD 2018 10
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Human Longevity Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 12
Venture Financing 13
Celularity Raises USD250 Million in Venture Financing 13
Celularity Raises Funds through Series A Financing 15
Human Longevity Raises US$70 Million In Venture Financing 16
Partnerships 17
Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 17
Human Longevity Enters into Agreement with Merck 19
Cypher Genomics Enters into Research Agreement with Clinic for Special Children 20
Cypher Genomics Enters into Co-Development Agreement with Celgene 21
Cypher Genomics Enters into Co-Promotion Agreement with Illumina 22
Licensing Agreements 23
Human Longevity Enters into Licensing Agreement with Celgene Cellular Therapeutics for PSC-100 23
Acquisition 24
Human Longevity Acquires LifebankUSA from Celgene Cellular Therapeutics 24
Human Longevity Inc – Key Competitors 25
Human Longevity Inc – Key Employees 26
Human Longevity Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Corporate Communications 28
Jul 13, 2018: Human Longevity Appoints Dr. David Karow, MD, Ph.D., As Interim Chief Executive Officer 28
Mar 19, 2018: Human Longevity, Inc. Hires Former Ancestry Executive, Scott Sorensen, As New Chief Technology Officer 29
Dec 01, 2017: Human Longevity Announces Executive Leadership Changes: Co-Founder J. Craig Venter, Ph.D. is Reappointed as CEO 30
May 25, 2017: Saturnino Fanlo Joins Human Longevity As Chief Financial Officer 31
May 02, 2017: Human Longevity Enhances Senior Leadership Team, Making Key Hires to Strengthen Commercialization and Operations 32
Jan 04, 2017: Human Longevity Hires Cynthia Collins, Healthcare Industry Leader, as New Chief Executive Officer 34
Legal and Regulatory 36
Apr 18, 2018: Human Longevity Clinical Labs Receives Accreditation from College of American Pathologists 36
Government and Public Interest 37
Feb 26, 2018: Human Longevity Scientists Publish Paper Diving Deeper into Non-Coding Genome Which Represents 98% of the Human Genome 37
Feb 05, 2018: New Metabolomic and Genomic-Informed Study Shows Use of Acetaminophen Has Unexpected Effects on Regulation of Sex Hormones 38
Product News 39
Aug 21, 2017: Celularity Accelerates Breakthrough Placental Discovery & Therapeutic Platform 39
Jul 03, 2017: Human Longevity Researchers Develop New Algorithm to Rapidly and Accurately Predict HLA Types Using Illumina Next Generation Sequencing Technology 40
Mar 28, 2018: Human Longevity Launches New Health Nucleus Products With Membership Component 41
Mar 06, 2017: In Largest Whole Genome Sequence Analysis Study, Human Longevity-Led Team Identifies Common-to-Rare Variants in the Human Blood Metabolome 42
Other Significant Developments 43
May 11, 2017: Human Longevity, Inc. Launches Pilot Program, Health Nucleus X 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Human Longevity Inc, Pharmaceuticals & Healthcare, Key Facts 2
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Human Longevity Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Human Longevity Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Human Longevity Inc, Medical Devices Deals, 2012 to YTD 2018 10
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina 12
Celularity Raises USD250 Million in Venture Financing 13
Celularity Raises Funds through Series A Financing 15
Human Longevity Raises US$70 Million In Venture Financing 16
Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 17
Human Longevity Enters into Agreement with Merck 19
Cypher Genomics Enters into Research Agreement with Clinic for Special Children 20
Cypher Genomics Enters into Co-Development Agreement with Celgene 21
Cypher Genomics Enters into Co-Promotion Agreement with Illumina 22
Human Longevity Enters into Licensing Agreement with Celgene Cellular Therapeutics for PSC-100 23
Human Longevity Acquires LifebankUSA from Celgene Cellular Therapeutics 24
Human Longevity Inc, Key Competitors 25
Human Longevity Inc, Key Employees 26
Human Longevity Inc, Other Locations 27
Human Longevity Inc, Subsidiaries 27

List of Figures
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Human Longevity Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Human Longevity Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Human Longevity Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • DASAN ZHONE SOLUTIONS, INC.:企業の戦略・SWOT・財務情報
    DASAN ZHONE SOLUTIONS, INC. - Strategy, SWOT and Corporate Finance Report Summary DASAN ZHONE SOLUTIONS, INC. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • GW Pharmaceuticals Plc (GWPH):医療機器:M&Aディール及び事業提携情報
    Summary GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the …
  • Outlook Therapeutics Inc (ONSIU):企業の財務・戦略的SWOT分析
    Summary Outlook Therapeutics Inc (Outlook Therapeutics), formerly Oncobiologics Inc, is a biopharmaceutical company that develops, manufactures and commercializes biosimilar products in the areas of ophthalmology. The company is investigating its lead product candidate, ONS-5010 an ophthalmic formul …
  • Medikit Co Ltd (7749):企業の製品パイプライン分析
    Summary Medikit Co Ltd (Medikit) is a medical equipment provider that offers vascular devices. The company offers IV catheter, hemodialysis and intervention products. Its products include supercath Z3V, supercath 5 safety IV catheter, supercath AZ, supercath CLS, i-works, seiha, parent plus, parent …
  • BoneSupport AB:企業の製品パイプライン分析
    Summary BoneSupport AB (BoneSupport), a subsidiary of Bonesupport Holding AB, is a orthobiologics company that develops, manufactures and markets injectable bioceramic bone graft substitutes for the treatment of fragility fractures caused by osteoporosis; bone voids and gaps caused by trauma; diseas …
  • Investec Private Bank (South Africa):企業の戦略・SWOT・財務情報
    Investec Private Bank (South Africa) - Strategy, SWOT and Corporate Finance Report Summary Investec Private Bank (South Africa) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Sanofi India Ltd (SANOFI):企業の財務・戦略的SWOT分析
    Summary Sanofi India Ltd (Sanofi India), formerly Aventis Pharma Ltd, a subsidiary of Sanofi is a healthcare company. It manufactures and markets pharmaceutical and prescription products. The company offers products in the form of capsules, tablets, injection, vials, ampoules, ointments, creams and …
  • RATP Group:企業の戦略・SWOT・財務情報
    RATP Group - Strategy, SWOT and Corporate Finance Report Summary RATP Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Mars, Incorporated:企業の戦略・SWOT・財務情報
    Mars, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Mars, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Metrion Biosciences Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Metrion Biosciences Ltd (Metrion Biosciences) is a contract research organization that offers ion channel drug discovery services. The organization offers cardiac safety screening services, neuroscience-related assays and platforms and translational assays. Its ion channel screening services …
  • Banner Corp:企業の戦略・SWOT・財務情報
    Banner Corp - Strategy, SWOT and Corporate Finance Report Summary Banner Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • PEN, Inc. (PENC):企業の財務・戦略的SWOT分析
    PEN, Inc. (PENC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Neuron Biopharma SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Neuron Biopharma SA (NBP) is a biotechnology company that discovers and develops biosolutions. The company offers pharmaceutical compounds to prevent and treat various neurodegenerative diseases. It discovers and assesses nutraceuticals, and development of diagnostic methods for the treatmen …
  • Propanc Biopharma Inc (PPCB):製薬・医療:M&Aディール及び事業提携情報
    Summary Propanc Biopharma Inc (Propanc), formerly Propanc Health Group Corp, is a clinical stage biopharmaceutical company, which manufactures products for the treat of metastatic, pancreatic, ovarian and colorectal cancers. The company’s lead product candidate, PRP, a once-a-day intravenous formula …
  • Alembic Pharmaceuticals Ltd (APLLTD):製薬・医療:M&Aディール及び事業提携情報
    Summary Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company which manufactures and markets generic pharmaceutical products. The company’s active pharmaceutical ingredients include macrolides, NSAIDs, and other drugs. It also offers branded formulations in the areas of antibiotics and antib …
  • Wexford Health Sources Inc:企業の戦略的SWOT分析
    Wexford Health Sources Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Fresenius Medical Care AG & Co KGaA (FME):企業の財務・戦略的SWOT分析
    Fresenius Medical Care AG & Co KGaA (FME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • TTCL Public Company Limited (TTCL):電力:M&Aディール及び事業提携情報
    Summary TTCL Public Company Limited (TTCL), a subsidiary of Italian-Thai Development Public Company Limited, is a provider of engineering and construction services. The company offers integrated engineering, procurement and construction (EPC) services, feasibility study and project management servic …
  • NetEnt AB (NET B):企業の財務・戦略的SWOT分析
    Summary NetEnt AB (NetEnt), formerly Net Entertainment NE AB, is a gaming solution provider. The company offers netent live, pooled jackpots, branded games, casinomodule, back office, touch, live casino and extend. It provides services such as business intelligence, regulated markets, iGaming media …
  • Cathedral Energy Services Ltd (CET):石油・ガス:M&Aディール及び事業提携情報
    Summary Cathedral Energy Services Ltd (Cathedral) is an oil and gas company that provides drilling and completion services. The company's services include horizontal and directional drilling services, flowback and production testing, measurement while drilling services, production testing services, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆